Imax To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Wednesday - Boston Scientific (NYSE:BS
Analysts updated price targets for several companies. Rosenblatt raised IMAX's target to $65, BTIG cut CAN's to $2, Piper Sandler adjusted TTAN and BRZE targets, Needham boosted VRNS, BTIG reduced BSX, Wedbush increased PHVS, Canaccord raised CHYM, Freedom Capital upped ABM, and Keybanc lifted INNV. All analysts maintained their respective ratings.
How this was made
The 30-second read
Why it matters
Analyst target changes provide updated valuation expectations but lack a single catalyst, offering modest trading ideas.
Market read
Price target revisions may influence short-term trading decisions for the listed stocks.
What to watch
Broader market momentum and macro data could dominate price action, reducing the effect of individual target changes.
Background
The article aggregates recent analyst price target adjustments for a set of listed companies.
Ticker impact
Rosenblatt raised Imax Corp price target from $60 to $65.
Potential modest price gain over next few days.
Target increase signals improved outlook, but no catalyst beyond analyst view.
BTIG cut Boston Scientific price target from $60 to $56.
Possible slight downside pressure.
Target reduction reflects concerns, but limited immediate impact.
BTIG slashed Canaan Inc price target from $3 to $2.
Likely modest decline.
Target cut signals weaker outlook; market may react.
Piper Sandler cut ServiceTitan price target from $115 to $110.
Small downside risk.
Target change reflects slight concerns, limited impact.
Piper Sandler raised Braze price target from $27 to $30.
Potential modest upside.
Higher target indicates better expectations.
Needham boosted Varonis Systems price target from $50 to $55.
Possible short-term rally.
Analyst confidence reflected in higher target.
Wedbush raised Pharvaris price target from $42 to $50.
Potential notable upside.
Large increase signals strong upside expectations.
Canaccord Genuity raised Chime Financial price target from $45 to $50.
Modest upside possible.
Analyst view improves outlook.
Market effects
Analyst target revisions across healthcare, tech, and industrials may slightly shift sector sentiment.
Primarily U.S. equities; limited regional effect.
Minimal global impact beyond individual stock adjustments.
Counterpoint
Target cuts may be overblown; price may hold steady despite analyst downgrades.
Key entities
- AnalystRosenblatt
Raised Imax price target.
- AnalystBTIG
Adjusted targets for Boston Scientific and Canaan.
